Prescription digital therapeutic reduces monthly migraine days, phase 3 study shows
A phase 3 study shows CT-132, a prescription digital therapeutic, significantly reduces monthly migraine days by 3.04 after 12 weeks, improving quality of life and disability scores, with no adverse events reported.
Related Clinical Trials
Reference News
A phase 3 study shows CT-132, a prescription digital therapeutic, significantly reduces monthly migraine days by 3.04 after 12 weeks, improving quality of life and disability scores, with no adverse events reported.
CT-132, an investigational prescription digital therapeutic, significantly reduced monthly migraine days (MMDs) in a phase 3 ReMMi-D trial, with a –3.04 MMD reduction over 12 weeks compared to sham (–0.9 MMDs; P = .005). Improvements in quality of life and disability were also observed, with CT-132 deemed safe and well-tolerated.